Nombre de la Acción | Símbolo de la Acción | Bolsa de Valores | Tipo de Valor |
---|---|---|---|
XBiotech Inc | XBIT | NASDAQ | Acción Común |
Precio de Apertura | Precio Mínimo | Precio Máximo | Precio de cierre | Precio Anterior |
---|---|---|---|---|
8.26 | 8.02 | 8.69 | 8.02 | 8.16 |
Noticias Recientes
Fecha | Hora | Fuente | Noticia |
---|---|---|---|
07/2/2024 | 11:36 | EDGAR2 | Form SC 13G/A - Statement of acquisition of beneficial.. |
07/2/2024 | 11:01 | EDGAR2 | Form SC 13G/A - Statement of acquisition of beneficial.. |
05/1/2024 | 09:48 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
04/1/2024 | 08:00 | EDGAR2 | Form 8-K - Current report |
04/1/2024 | 08:00 | GLOBE | XBiotech to Begin Constructing New R&D Facility on its.. |
14/11/2023 | 08:00 | GLOBE | Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in.. |
09/11/2023 | 13:41 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
26/9/2023 | 08:00 | GLOBE | XBiotech Announces Enrollment Completion of Phase I Clinical.. |
30/8/2023 | 08:00 | GLOBE | XBiotech Announces Enrollment Completion of Phase II,.. |
11/8/2023 | 10:18 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
08/8/2023 | 10:47 | GLOBE | XBiotech Announces First Patient Begins Novel Natrunix.. |
22/5/2023 | 08:00 | GLOBE | FDA Authorizes Phase II Study for Natrunix in Rheumatoid.. |
17/5/2023 | 08:00 | GLOBE | XBiotech Commences Tender Offer to Purchase up to.. |